DSM informs market on the announced sale of DSM Sinochem Pharmaceuticals to Bain Capital

Heerlen, NL, 29 Jun 2018 18:45 CEST

Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, informs its stakeholders that Bain Capital today announced the proposed acquisition of DSM Sinochem Pharmaceuticals (DSP). DSM and Sinochem Group each own 50% of the shares of DSP. The transaction is expected to be completed in the fourth quarter of 2018, subject to customary regulatory approvals and consultations.

DSM will receive about €250 million for its equity stake, excluding an earn-out (estimated at around €50m) and transaction costs. DSM anticipates a book profit on the transaction to be recognized upon closing. DSM expects to receive approximately €275 million in cash following closing, including repayment of debt and after transaction costs. More information regarding the acquisition of DSP by Bain Capital can be found in the press release issued by Bain Capital and DSP on 29 June 2018.